Does Rallies show Form 4 insider transactions for ACRV?

Yes. Rallies tracks ACRV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ACRV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACRV. It does not provide personalized investment advice.

ACRV (Acrivon Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Acrivon Therapeutics, Inc. Common Stock (ACRV) is a publicly traded Healthcare sector company. As of May 21, 2026, ACRV trades at $1.81 with a market cap of $70.62M and a P/E ratio of -0.85. ACRV moved +10.00% today. Year to date, ACRV is -23.14%; over the trailing twelve months it is +40.80%. Its 52-week range spans $1.05 to $8.74. Analyst consensus is strong buy with an average price target of $11.20. Rallies surfaces ACRV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ACRV stock inside the company?

Recent ACRV insider activity includes Blume-Jensen Peter bought 49.00K, Levy Adam D. bought 8.83K, Devroe Eric bought 10.00K, PERCEPTIVE ADVISORS LLC sold 298.89K, and PERCEPTIVE ADVISORS LLC sold 437.88K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ACRV Key Metrics

Key financial metrics for ACRV
Metric	Value
Price	$1.81
Market Cap	$70.62M
P/E Ratio	-0.85
EPS	$-2.02
Dividend Yield	0.00%
52-Week High	$8.74
52-Week Low	$1.05
Volume	76
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-77.91M
Gross Margin	0.00%

Recent ACRV Insider Trades

Blume-Jensen Peter bought 49.00K (~$82.12K) on Jan 14, 2026.
Levy Adam D. bought 8.83K (~$15.00K) on Jan 14, 2026.
Devroe Eric bought 10.00K (~$17.22K) on Jan 13, 2026.
PERCEPTIVE ADVISORS LLC sold 298.89K (~$400.51K) on May 1, 2025.
PERCEPTIVE ADVISORS LLC sold 437.88K (~$617.41K) on Apr 30, 2025.

Latest ACRV News

Acrivon Preclinical Data Showcase ACR-368 and ACR-2316 Synergies with PD-L1 and ADC Topo1 — Apr 17, 2026
Acrivon’s ACR-368 Shows 52% Response Rate, Expands Trials with Two New Cohorts — Mar 19, 2026
Acrivon’s ACR-368 Shows Potent Synergy with Topo1 ADCs; ACR-2316 Yields Durable Tumor Regression — Mar 17, 2026
Acrivon Therapeutics Reports 52% ORR and 74% DCR in Serous Endometrial Cancer — Feb 27, 2026
Acrivon Launches CLIA-Certified Watertown Lab, Targets H1 2026 Operations — Feb 18, 2026

ACRV Analyst Consensus

6 analysts cover ACRV: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.20.

Common questions about ACRV

Who is trading ACRV stock inside the company?: Recent ACRV insider activity includes Blume-Jensen Peter bought 49.00K, Levy Adam D. bought 8.83K, Devroe Eric bought 10.00K, PERCEPTIVE ADVISORS LLC sold 298.89K, and PERCEPTIVE ADVISORS LLC sold 437.88K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ACRV?: Yes. Rallies tracks ACRV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ACRV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACRV. It does not provide personalized investment advice.